Cargando…

Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form

The objective of the present work was to develop a stability-indicating RP-HPLC method for duloxetine hydrochloride (DUL) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid hydrolysis. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Chhalotiya, Usmangani K., Bhatt, Kashyap K., Shah, Dimal A., Baldania, Sunil L.
Formato: Texto
Lenguaje:English
Publicado: Österreichische Apotheker-Verlagsgesellschaft 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007604/
https://www.ncbi.nlm.nih.gov/pubmed/21179321
http://dx.doi.org/10.3797/scipharm.1009-11
_version_ 1782194394658504704
author Chhalotiya, Usmangani K.
Bhatt, Kashyap K.
Shah, Dimal A.
Baldania, Sunil L.
author_facet Chhalotiya, Usmangani K.
Bhatt, Kashyap K.
Shah, Dimal A.
Baldania, Sunil L.
author_sort Chhalotiya, Usmangani K.
collection PubMed
description The objective of the present work was to develop a stability-indicating RP-HPLC method for duloxetine hydrochloride (DUL) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid hydrolysis. The drug was found to be stable to dry heat, photodegradation, oxidation and basic condition attempted. Successful separation of the drug from the degradation products formed under acidic stress conditions was achieved on a Hypersil C-18 column (250 mm × 4.6 mm id, 5μm particle size) using acetonitrile: 0.01 M potassium dihydrogen phosphate buffer (pH 5.4 adjusted with orthophosphoric acid) (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min. Quantification was achieved with photodiode array detection at 229 nm over the concentration range 1–25 μg/ml with range of recovery 99.8–101.3 % for DUL by the RP-HPLC method. Statistical analysis proved the method to be repeatable, specific, and accurate for estimation of DUL. It can be used as a stability-indicating method due to its effective separation of the drug from its degradation products,
format Text
id pubmed-3007604
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Österreichische Apotheker-Verlagsgesellschaft
record_format MEDLINE/PubMed
spelling pubmed-30076042010-12-22 Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form Chhalotiya, Usmangani K. Bhatt, Kashyap K. Shah, Dimal A. Baldania, Sunil L. Sci Pharm Original Papers The objective of the present work was to develop a stability-indicating RP-HPLC method for duloxetine hydrochloride (DUL) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid hydrolysis. The drug was found to be stable to dry heat, photodegradation, oxidation and basic condition attempted. Successful separation of the drug from the degradation products formed under acidic stress conditions was achieved on a Hypersil C-18 column (250 mm × 4.6 mm id, 5μm particle size) using acetonitrile: 0.01 M potassium dihydrogen phosphate buffer (pH 5.4 adjusted with orthophosphoric acid) (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min. Quantification was achieved with photodiode array detection at 229 nm over the concentration range 1–25 μg/ml with range of recovery 99.8–101.3 % for DUL by the RP-HPLC method. Statistical analysis proved the method to be repeatable, specific, and accurate for estimation of DUL. It can be used as a stability-indicating method due to its effective separation of the drug from its degradation products, Österreichische Apotheker-Verlagsgesellschaft 2010 2010-10-25 /pmc/articles/PMC3007604/ /pubmed/21179321 http://dx.doi.org/10.3797/scipharm.1009-11 Text en © Chhalotiya et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Chhalotiya, Usmangani K.
Bhatt, Kashyap K.
Shah, Dimal A.
Baldania, Sunil L.
Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form
title Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form
title_full Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form
title_fullStr Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form
title_full_unstemmed Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form
title_short Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form
title_sort development and validation of a stability-indicating rp-hplc method for duloxetine hydrochloride in its bulk and tablet dosage form
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007604/
https://www.ncbi.nlm.nih.gov/pubmed/21179321
http://dx.doi.org/10.3797/scipharm.1009-11
work_keys_str_mv AT chhalotiyausmanganik developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform
AT bhattkashyapk developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform
AT shahdimala developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform
AT baldaniasunill developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform